EA201491339A1 - Замещенные аннеллированные пиримидины и триазины и их применение - Google Patents

Замещенные аннеллированные пиримидины и триазины и их применение

Info

Publication number
EA201491339A1
EA201491339A1 EA201491339A EA201491339A EA201491339A1 EA 201491339 A1 EA201491339 A1 EA 201491339A1 EA 201491339 A EA201491339 A EA 201491339A EA 201491339 A EA201491339 A EA 201491339A EA 201491339 A1 EA201491339 A1 EA 201491339A1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazines
pyrimidines
application
prevention
treatment
Prior art date
Application number
EA201491339A
Other languages
English (en)
Other versions
EA025837B1 (ru
Inventor
Маркус Фолльманн
Ёханнес-Петер Сташ
Горден Редлих
Нильс Грибено
Дитер Ланг
Франк Вундер
Вальтер Хюбш
Александрос Вакалопулос
Адриан Терстееген
Original Assignee
Байер Интеллектуэль Проперти Гмбх
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559479&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491339(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Интеллектуэль Проперти Гмбх, Байер Фарма Акциенгезельшафт filed Critical Байер Интеллектуэль Проперти Гмбх
Publication of EA201491339A1 publication Critical patent/EA201491339A1/ru
Publication of EA025837B1 publication Critical patent/EA025837B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Заявка касается новых замещеных аннеллированных пиримидинов и триазинов, способа их получения, их применение отдельно или в комбинациях для лечения и/или предупреждения заболеваний, а также их применения для приготовления лекарственных средств для лечения и/или предупреждения заболеваний, в частности для лечения и/или предупреждения сердечно-сосудистых заболеваний.
EA201491339A 2012-01-11 2013-01-10 Замещенные аннеллированные пиримидины и триазины EA025837B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012200349A DE102012200349A1 (de) 2012-01-11 2012-01-11 Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
PCT/EP2013/050381 WO2013104703A1 (de) 2012-01-11 2013-01-10 Substituierte annellierte pyrimidine und triazine und ihre verwendung

Publications (2)

Publication Number Publication Date
EA201491339A1 true EA201491339A1 (ru) 2015-01-30
EA025837B1 EA025837B1 (ru) 2017-02-28

Family

ID=47559479

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491339A EA025837B1 (ru) 2012-01-11 2013-01-10 Замещенные аннеллированные пиримидины и триазины

Country Status (29)

Country Link
US (2) US20140357637A1 (ru)
EP (1) EP2802592A1 (ru)
JP (1) JP6251183B2 (ru)
KR (1) KR20140114416A (ru)
CN (1) CN104812762B (ru)
AP (1) AP2014007844A0 (ru)
AU (1) AU2013208968A1 (ru)
BR (1) BR112014016971A8 (ru)
CA (1) CA2860855A1 (ru)
CL (1) CL2014001779A1 (ru)
CO (1) CO7000776A2 (ru)
CR (1) CR20140327A (ru)
CU (1) CU20140082A7 (ru)
DE (1) DE102012200349A1 (ru)
DO (1) DOP2014000160A (ru)
EA (1) EA025837B1 (ru)
EC (1) ECSP14008556A (ru)
GT (1) GT201400147A (ru)
HK (1) HK1211585A1 (ru)
IL (1) IL233460A0 (ru)
MA (1) MA35844B1 (ru)
MX (1) MX2014008201A (ru)
NZ (1) NZ626394A (ru)
PE (1) PE20142293A1 (ru)
PH (1) PH12014501595A1 (ru)
SG (2) SG10201605655UA (ru)
TN (1) TN2014000298A1 (ru)
WO (1) WO2013104703A1 (ru)
ZA (1) ZA201405042B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
US9090610B2 (en) * 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200352A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
CA2866213A1 (en) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Substituted azabicycles and use thereof
AU2013353117A1 (en) 2012-11-30 2015-06-04 Astellas Pharma Inc. Imidazopyridine compound
ES2616042T3 (es) * 2013-03-01 2017-06-09 Bayer Pharma Aktiengesellschaft Pirazolopiridinas sustituidas con bencilo y su uso
WO2014131760A1 (de) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
TW201542569A (zh) * 2013-07-10 2015-11-16 Bayer Pharma AG 苯甲基－１Ｈ－吡唑并［３，４－ｂ］吡啶類及其用途
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9611278B2 (en) 2013-12-11 2017-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
EP3107920B1 (de) * 2014-02-19 2017-10-18 Bayer Pharma Aktiengesellschaft 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
US20170233413A1 (en) 2014-08-29 2017-08-17 Bayer Pharma Aktiengesellschaft Substituted annulated pyrimidines and use thereof
US20170240566A1 (en) 2014-08-29 2017-08-24 Bayer Pharma Aktiengesellschaft Amino-substituted annulated pyrimidines and use thereof
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之***并吡基衍生物
CN107001361A (zh) 2014-12-02 2017-08-01 拜耳医药股份有限公司 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途
EA201792346A1 (ru) 2015-05-06 2018-05-31 Байер Фарма Акциенгезельшафт ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc)
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
EP3310782B1 (en) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
HUE052337T2 (hu) 2015-07-23 2021-04-28 Bayer Pharma AG Oldható guanilát-cikláz stimulátorai/aktivátorai a neutrális endopeptidáz egy inhibitorával (NEP-inhibitor) és/vagy egy angiotenzin All-antagonistával kombinációban és ezek alkalmazása
KR101753652B1 (ko) * 2015-10-21 2017-07-05 한국화학연구원 N-아릴-1h-피라졸로피리딘-3-아민 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017200857A1 (en) 2016-05-18 2017-11-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
ES2957159T3 (es) 2016-09-02 2024-01-12 Cyclerion Therapeutics Inc Estimuladores de SGC fusionados bicíclicos
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
AU2018252099B2 (en) 2017-04-11 2021-08-12 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
WO2020014504A1 (en) 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
CN113368240B (zh) * 2021-06-13 2022-08-02 重庆医科大学 一种二茂铁基金属有机框架纳米粒及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8601208A1 (es) 1984-11-26 1985-11-01 Fordonal Sa Procedimiento de preparacion de un derivado de piracina.
JPS63139949A (ja) 1986-12-02 1988-06-11 Fuji Photo Film Co Ltd 新規ピラゾロン染料
SE8704248D0 (sv) 1987-10-30 1987-10-30 Haessle Ab Medical use
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
EP0934311B1 (de) 1996-10-14 2009-05-13 Bayer HealthCare AG Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE10021069A1 (de) 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
EP1339716B1 (de) 2000-11-22 2004-11-03 Bayer HealthCare AG lactam-substituierte pyrazolopyridinderivate
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
EP1626045B1 (en) 2003-05-09 2010-09-08 Asahi Glass Company, Limited Processes for producing 3-substituted 2-chloro-5-fluoropyridine or salt thereof
CN100355732C (zh) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 2－氯－5－氟－烟酸酯及酸的制备方法
JP4996257B2 (ja) 2004-01-31 2012-08-08 アクチミス ファーマシューティカルズ インコーポレーテッド イミダゾ［１，２−ｃ］ピリミジニル酢酸誘導体
CN101146796A (zh) 2005-01-26 2008-03-19 先灵公司 作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
TW200916468A (en) 2007-07-31 2009-04-16 Vertex Pharma Process for preparing 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine and derivatives thereof
WO2009145814A2 (en) 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
JP5314192B2 (ja) 2009-08-07 2013-10-16 アルカテル−ルーセント ＶｏＩＰ会話のハンドオーバでのブレーク継続時間を低減するための方法及び装置
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2800541C (en) 2010-05-27 2016-03-22 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2590987B1 (de) 2010-07-09 2016-03-09 Bayer Intellectual Property GmbH Annellierte 4-aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase
EP2590979A1 (de) * 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040234A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
WO2012152629A1 (de) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituierte imidazopyridine und imidazopyridazine und ihre verwendung
US9090610B2 (en) 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
AR086589A1 (es) 2011-05-30 2014-01-08 Astellas Pharma Inc Compuestos imidazopiridina
JP6109161B2 (ja) 2011-07-06 2017-04-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ヘテロアリール置換ピラゾロピリジン類およびその使用
CA2844730A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
PE20141582A1 (es) 2011-09-02 2014-11-06 Bayer Ip Gmbh Pirimidinas anilladas sustituidas y uso de las mismas
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
CA2866213A1 (en) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Substituted azabicycles and use thereof
WO2014131760A1 (de) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung
ES2616042T3 (es) 2013-03-01 2017-06-09 Bayer Pharma Aktiengesellschaft Pirazolopiridinas sustituidas con bencilo y su uso
TW201542569A (zh) 2013-07-10 2015-11-16 Bayer Pharma AG 苯甲基－１Ｈ－吡唑并［３，４－ｂ］吡啶類及其用途

Also Published As

Publication number Publication date
HK1211585A1 (en) 2016-05-27
ECSP14008556A (es) 2015-12-31
US20140357637A1 (en) 2014-12-04
DE102012200349A1 (de) 2013-07-11
AP2014007844A0 (en) 2014-07-31
JP6251183B2 (ja) 2017-12-20
ZA201405042B (en) 2016-08-31
AU2013208968A1 (en) 2014-07-24
NZ626394A (en) 2016-11-25
CU20140082A7 (es) 2014-10-30
PH12014501595A1 (en) 2014-10-08
JP2015503605A (ja) 2015-02-02
CO7000776A2 (es) 2014-07-21
BR112014016971A2 (pt) 2017-06-13
CR20140327A (es) 2014-11-26
US20150274754A1 (en) 2015-10-01
KR20140114416A (ko) 2014-09-26
GT201400147A (es) 2015-04-06
EP2802592A1 (de) 2014-11-19
PE20142293A1 (es) 2014-12-19
MA35844B1 (fr) 2014-12-01
MX2014008201A (es) 2014-08-08
IL233460A0 (en) 2014-08-31
SG10201605655UA (en) 2016-09-29
CN104812762A (zh) 2015-07-29
EA025837B1 (ru) 2017-02-28
BR112014016971A8 (pt) 2017-07-04
WO2013104703A1 (de) 2013-07-18
TN2014000298A1 (en) 2015-12-21
CA2860855A1 (en) 2013-07-18
US9505786B2 (en) 2016-11-29
SG11201403345UA (en) 2014-09-26
DOP2014000160A (es) 2014-08-31
CL2014001779A1 (es) 2014-11-03
CN104812762B (zh) 2018-01-16

Similar Documents

Publication Publication Date Title
EA201491339A1 (ru) Замещенные аннеллированные пиримидины и триазины и их применение
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201590251A1 (ru) Новые 5-аминотетрагидрохинолин-2-карбоновые кислоты и их применение
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA202090662A3 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201391106A1 (ru) Новые гетероциклические производные
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
EA201600288A1 (ru) Замещенные фенилаланиновые производные

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU